South Rampart Pharma,Inc. is developing a new class of small molecule, non-opioid pain medicines.
These proprietary South Rampart Pharma,Inc. (SRP) compounds have been effective in reducing both pain and fever in preclinical studies without liver and kidney toxicity that are associated with current common over the counter analgesics. SRP compounds are non-opioid, greatly reducing abuse potential.
Our lead clinical entity, SRP-001, is currently undergoing Phase 1 trials evaluating the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses.